Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Income: 2016-2025

Historic Net Income for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $540,000.

  • Akebia Therapeutics' Net Income rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Net Income of $540,000 as of Q3 2025, which was up 118.62% from $247,000 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Net Income registered a high of $29.0 million during Q2 2022, and its lowest value of -$84.3 million during Q2 2021.
  • For the 3-year period, Akebia Therapeutics' Net Income averaged around -$10.4 million, with its median value being -$11.2 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first soared by 134.44% in 2022, then tumbled by 3,814.01% in 2024.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Net Income stood at -$70.4 million in 2021, then soared by 90.76% to -$6.5 million in 2022, then surged by 109.44% to $614,000 in 2023, then tumbled by 3,814.01% to -$22.8 million in 2024, then surged by 102.69% to $540,000 in 2025.
  • Its Net Income was $540,000 in Q3 2025, compared to $247,000 in Q2 2025 and $6.1 million in Q1 2025.